Until Labs

Executive Summary

Until Labs is pioneering reversible cryopreservation technology for human organs, addressing the critical shortage of donor organs. By vitrifying organs into a glass-like state without ice formation, the company enables long-term preservation and reliable transport, potentially revolutionizing transplant logistics. Its current focus on organs serves as a foundational step toward its ambitious vision of whole-body reversible cryopreservation. Despite being early-stage, Until Labs leverages cutting-edge biophysics and biomaterials to overcome historic challenges in cryobiology, positioning itself at the forefront of a transformative medical field.

Upcoming Catalysts (preview)

• Q4 2026Publication of preclinical proof-of-concept data in a peer-reviewed journal60% success
• Q2 2027Strategic partnership with a major organ procurement organization40% success
• Q1 2027Series B financing or government grant to scale R&D50% success